Poster Session B
Systemic lupus erythematosus (SLE)
Guillermo Pons-Estel, MD,PhD
CREAR
Rosario, Argentina
No financial relationships with ineligible companies to disclose
One-thousand eighty-one patients were enrolled in GLADEL 2.0 with 364 patients included in this analysis: 195 (53.5%) in Group III and 169 (46.4%) in Group IV. At the 12-month follow-up, 13/364 (3.5%) patients had died, 14/364 (3.8%) had been lost to follow-up, and 28/364 (7.6%) had incomplete data; therefore, the calculation of renal response was carried out in the remaining 309 patients. Table 1 describes the characteristics of patients with LN. Table 2 shows that patients who achieved renal response (complete or partial) had a shorter disease duration, greater use of pulse corticosteroids and IV cyclophosphamide, a lower chronicity index and all belonged to the LN incident group. When comparing complete vs partial response, patients who achieved complete response had lower baseline proteinuria and creatinine values, belonged to histological Class III and had lower SLEDAI.
Conclusion: Renal response was achieved in 64% of patients having their first episode of LN, with lower chronicity rates in the biopsy and a lower SLEDAI. Pulsed corticosteroids and IV cyclophosphamide continue to be the options chosen by treating physicians. More data in the follow-up will allow us to evaluate the persistence of this response over time and what factors may influence it.
Table 1. Clinical Characteristics, Disease Activity, Damage Index, and Treatment at Cohort Entry
Table 2. Partial, Complete and No Response at 12 Months
R. Quintana: None; R. Nieto: None; D. Ávila: None; R. Serrano Morales: None; G. Harvey: None; L. Hernandez: None; K. Roberts: None; M. Scolnik: AstraZeneca, 1, GlaxoSmithKlein(GSK), 1, 6, Janssen, 1, 6, Pfizer, 1, 6, Roche, 1, 6; C. Funes Soaje: None; P. Alba: None; V. Saurit: None; M. Garcia: None; G. Berbotto: None; V. BELLOMIO: None; W. Grageda: None; G. Gómez: None; C. Pisoni: None; A. Malvar: F. Hoffmann-La Roche Ltd, 2, Genentech Inc., 2; V. Juarez: None; N. Da Silva: None; O. MONTICIELO: AbbVie/Abbott, 6, AstraZeneca, 6, GlaxoSmithKlein(GSK), 6, Janssen, 6, UCB, 6; H. Mariz: None; F. Ribeiro: None; E. Borba: None; L. Parente: AstraZeneca, 6, Janssen, 6; E. Torres: None; O. Neira: None; L. Massardo: None; G. Aroca Martínez: None; C. Davila: None; G. López: None; C. Toro-Gutierrez: None; M. Moreno: None; A. Zuñiga: None; M. Saavedra Salinas: None; M. Hernandez: None; H. Fragoso-Loyo: None; L. Silveira Torre: None; I. De La Torre: None; C. Mendoza: None; M. Hernández: None; J. Esquivel-Valerio: None; I. Colman: None; J. Losanto: None; C. Mora Trujillo: None; K. Corrales: None; R. Louis: None; M. Rebella: None; Á. Danza: None; M. Ugarte-Gil: AstraZeneca, 1, 6, Ferrer, 1, GlaxoSmithKlein(GSK), 6, Janssen, 5, Tecnofarma, 2, 6, 12, Travel Support; G. Alarcon: None; U. Sbarigia: Janssen, 3, Johnson & Johnson, 11; F. Zazzetti: Janssen, 3, Johnson & Johnson, 11; A. Orillion: Janssen, 3, Johnson & Johnson, 11; G. Pons-Estel: AbbVie/Abbott, 1, AstraZeneca, 1, 6, Boehringer-Ingelheim, 6, GlaxoSmithKlein(GSK), 1, 5, 6, Janssen, 1, 5, 6, Werfen/Inova, 6; B. Pons-Estel: AstraZeneca, 1, 6, GSK, 1, 6, Janssen, 1, 6.